Molecular Mechanisms of the Dysregulated Immune Response to Ebola Virus

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 5P01AI150585-02

Grant search

Key facts

  • Disease

    Ebola
  • Start & end year

    2021
    2026
  • Known Financial Commitments (USD)

    $2,528,313
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR Alexander Bukreyev
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF TEXAS MED BR GALVESTON
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

OVERALL: PROJECT SUMMARY/ABSTRACT The central hypothesis of the proposed P01 Program is that Ebola virus infection leads to cell-type specific transcriptional, posttranscriptional, and posttranslational alterations that create aberrant counterproductive responses of immune cells, leading to a dysregulated immune response, which paradoxically produces "immune paralysis" and hyperinflammation. To address the hypothesis, three Research Projects are proposed. Research Project 1 focuses on pathogenic mechanisms at the transcriptional level, while Research Project 2 focuses on posttranscriptional events, and Research Project 3 focuses on posttranslational modifications, each contributing to the dysregulated immune response to Ebola virus. The dysregulated immune response is responsible for most of the pathogenesis observed in Ebola virus disease. All projects require the BSL-4 Core (Core B), which will be responsible for performing infections of human immune and nonimmune cells, nonhuman primates, and the initial steps of experiments that involve infectious virus. Importantly, Core B will provide each of the research projects samples from the same experimental samples insuring that data from each project can be compared directly-this is a unique feature of this P01 Program. The Proteogenomics Core (Core C) will be responsible for massive parallel sequencing and mass spectrometry-based studies. The Bioinformatics and Modeling Core (Core D) is critical for generating tools employed in the experimental designs, including statistical help for OMICS experiments, analyzing OMICS data and integrating OMICS data into networks that model the behavior of various cell populations infected with EBOV. The work done in Core D will synthesize a model to explain how transcriptional, posttranscriptional, and posttranslational responses of individual cell populations lead to immune dysregulation. The comprehensive picture painted by this collaborative effort will revolutionize our understanding of the immunopathogenesis of severe acute viral infections (e.g., immune imbalance seen in COVID-19). The Administrative Core (Core A) will be responsible for strategic planning, continual evaluation, and communication and coordination of activities among the various components of the project according to a detailed management plan. The expected outcomes will contribute substantially to our knowledge of the fundamental mechanisms of the immunopathogenesis of EBOV infections toward the development of effective countermeasures. The expected outcomes will include (1) detailed knowledge of transcriptional mechanisms leading to the dysregulated immune response to EBOV, (2) elucidation of the role of posttranscriptional mechanisms in the dysregulated immune response to EBOV, (3) elucidation of the role of posttranslational mechanisms in the dysregulated immune response to EBOV, and (4) experimental validation of the identified pathogenic mechanisms and their targeting. The proposed tightly coordinated and comprehensive analysis has not been done before for any virus.